SCHEMBL6941573

SCHEMBL6941573

COc1c(Cl)cc(CBr)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 2/20 0.44
DBH P09172 1/20 0.44
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
HTR2A P28223 4/20 0.40
HTR2C P28335 4/20 0.40
HTR1A P08908 3/20 0.40
DRD2 P14416 3/20 0.40
DRD4 P21917 3/20 0.40
DRD3 P35462 3/20 0.40
PTGS2 P35354 1/20 0.40
HPGD P15428 1/20 0.37
POLB P06746 1/20 0.36
THRB P10828 1/20 0.36
RORC P51449 1/20 0.36
HTR2B P41595 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19924948 0.86 KMT2A (0.36) ALDH1A1KDM4EGAADBHMEN1
SCHEMBL19629677 0.79 PTGS2 (0.58) ALDH1A1KDM4EGAADBHMEN1
SCHEMBL10632545 0.79 ALDH1A1 (0.46) ALDH1A1KDM4EGAADBHMEN1
SCHEMBL2388964 0.77 MAPT (0.50) ALDH1A1KDM4EGAADBHMEN1
SCHEMBL6943761 0.77 KDM4E (0.48) ALDH1A1KDM4EGAADBHMEN1
SCHEMBL29413276 0.77 KMT2A (0.65) ALDH1A1GAAMEN1KMT2AHPGD
SCHEMBL365268 0.77 KMT2A (0.65) ALDH1A1GAAMEN1KMT2AHPGD
SCHEMBL722969 0.76 PTGS2 (0.67) ALDH1A1KDM4EMEN1KMT2AHTR2A
Hydrochloric Acid SCHEMBL3113761 0.76 KDM4E (0.47) ALDH1A1KDM4EGAADBHMEN1
SCHEMBL11845896 0.76 ALDH1A1 (0.43) ALDH1A1KDM4EGAADBHMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN disclosed
EP-1080069-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-03-07 EP disclosed
WO-1999054284-A1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A ALDH1A1 253/4885KDM4E 2029/4885GAA 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.